patent/KR-101089111-B1

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101089111-B1

Outgoing Links

Predicate	Object
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1777 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
filingDate	2007-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate	2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate	2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	KR-101089111-B1
titleOfInvention	Pharmaceutical Compositions of HBPLP-1, Exendin-4, and Their Analogs
abstract	The present invention relates to hGLP-1 (7-36) -NH 2 and its analogs and derivatives, hGLP-1 (7-37) -OH and its analogs and derivatives, and / or exendin-4 and its analogs and Pharmaceutical composition comprising at least one peptide compound selected from the group consisting of derivatives, zinc and solvents, clear solutions, or aqueous mixtures, suspensions or semisolid pharmaceutical compositions, wherein at least 95% of the peptide compounds are dissolved in the solvent. It relates to a composition.
priorityDate	2006-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004235710-A1
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466499401

Total number of triples: 33.